TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05017909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face education
Description: Face to face education techniques on the acquisition of the mothering Role

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based education
Description: web based education techniques on the acquisition of the mothering Role

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No education
Description: Control group will not be educated
Study: NCT05522309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ET0111
Description: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 21 days in duration with ET0111 administered, once daily (QD).
Study: NCT05830279

Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Genotyping for CYP2D6 and CYP2C19

Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Genotyping for CYP2D6 and CYP2C19

Intervention type: GENETIC
Intervention: Pharmacogenetic testing
Description: Genotyping for CYP2D6 and CYP2C19

Intervention type: OTHER
Intervention: Drug-Drug interaction analysis
Description: Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.

Intervention type: OTHER
Intervention: Drug-Drug interaction analysis
Description: Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.

Intervention type: OTHER
Intervention: Drug-Drug interaction analysis
Description: Evaluating potential drug interactions with CYP2D6, CYP2C9 and CYP3A4 inhibitors and inducers using the Medical Letter.
Study: NCT05771844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Electrical Stimulation
Description: Oscillating electrical current
Study: NCT04685408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM
Description: TEAM is informed by principles of social cognitive theory TEAM uses nurses and peer educator dyads (PEDs) composed of patients and their care partners to co-deliver an intervention intended to help reduce future stroke risk. Team begins with one 60-minute 1:1 orientation session, in which the nurse and PED meet with the patient and his/her care partner. This is followed by 6 hour-long group sessions with 6-8 patients and their care partners held approximately weekly. The first orientation session will be done approximately 1 week post baseline, followed by group sessions were done at 2, 4, 6, 8, 10 and 12 weeks post-baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ETAU
Description: ETAU will consist of an orientation visit with a nurse who will provide patient-education materials on stroke risk adapted from the American Heart Association materials and cover common risk factors such as hypertension, obesity, high salt/high fat diet and diabetes. Patients will also receive basic written information in their language of preference and tailored to the reading level of most patients at the clinic. Patients will be offered the opportunity to bring a family member with them to this visit who may also ask questions and who can assist them with understanding written materials for those with limited literacy. The nurse in ETAU will then follow-up with participants with a series of 9 brief phone calls spaced out over the course of 6 months (approximately every 2 weeks during months 1 and 2, then approximately monthly thereafter). Content will reinforce materials provided in the orientation visit and the nurse will be available to answer questions that may arise.
Study: NCT05400902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC Combined with Tislelizumab and Apatinib
Description: Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for 2 hours, 5-fluorouracil 400 mg/m2 arterial infusion for 10 minutes, 5-fluorouracil 1200 mg/m2 infusion for 23 hours. Every 3 weeks, no more than 4 cycles of HAIC treatment.~Sintilimab and Bevacizumab treatment: start at 0-3 days after the end of hepatic arterial infusion chemotherapy: Sintilimab 200 mg ivdrip, Q3W; Bevacizumab 15 mg/kg ivdrip, Q3W
Study: NCT04836416

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT06446908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth coaching for liver disease
Description: This study is an open-label, mono-centred, single-case experimental design with multiple base levels. The study will comprise 3 phases, alternating periods of observation (A) and 1 period of counselling (B) with an A1-B-A2 design.~PA will be assessed continuously using an accelerometer for 7 to 14 days per (A) phase. During phase (B), participants will receive the intervention, i.e. 6 x 45-minute, real-time, face-to-face, virtual sessions with a PA counsellor.
Study: NCT05545865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Flavanol Cocoa Powder
Description: Measure the response 2 and 6 hours post low flavanol cocoa intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Flavanol Cocoa Powder
Description: Measure the response 2 and 6 hours post low flavanol cocoa intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Flavanol Cocoa Powder
Description: Measure the response 2 and 6 hours post high flavanol cocoa intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Flavanol Cocoa Powder
Description: Measure the response 2 and 6 hours post high flavanol cocoa intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 2 servings
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vine to Bar Chocolate - 2 servings
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 2 servings
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 2 servings
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 1 serving
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vine to Bar Chocolate - 1 serving
Description: Measure the response 2 and 6 hours post chocolate intake
Study: NCT05194618

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valerian - lavender
Description: 1 tablet per day, half hour before bedtime, day 1 to day 28

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day, half hour before bedtime, day 1 to day 28
Study: NCT05383768

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
Description: Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
Description: Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
Description: Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C
Description: Intervention 1: restoration with one-time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 2: Restoration with five time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).~Intervention 3: Restoration with ten time preheated conventional bulk-fill resin composite, X-tra fill (VOCO, GERMANY) at 68◦C (Yang et al., 2020).
Study: NCT04565301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: adductor canal block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: adductor canal block

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl solutions
Description: adductor canal block
Study: NCT05594914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 plus TC regimen(paclitaxel liposome , carboplatin), once every 3 weeks (Q3W), induction treatment for 2 cycles; Subsequently, AK104 plus TC regimen is combined with radiotherapy for 2 cycles.
Study: NCT06543069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
Description: Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
Study: NCT05479955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 minutes skin to skin contact
Description: Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. The women in this group received 5 minutes of skin-to-skin contact as a clinic routine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60 minutes skin to skin contact
Description: Skin-to-skin contact is defined as placing a naked baby on the mother's bare stomach or breast for at least one hour immediately after birth. In line with the recommendation of the World Health Organization, 60 minutes of skin-to-skin contact was applied to the women in this group.
Study: NCT05414279

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sodium determination
Description: Through a single finger prick 10 drops of capillary blood will be drawn. The venous blood sample will be taken through a standard venipuncture. Both samples will be send to the lab for indirect sodium determination
Study: NCT04810676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501, D745, D150
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study: NCT06077123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contigo Application
Description: Contigo, a smartphone application, aims to achieve two main objectives: monitoring cancer patients for early detection of oncology drug toxicity signs and providing educational content to empower patients in handling clinical challenges tied to their diagnosis and treatment. Monitoring involves modules and sub-modules where patients input experiences through oncology-related questionnaires. Weekly checks for chemotherapy toxicity-associated symptoms use a validated questionnaire (PRO-CTCAE). Severe toxicity triggers immediate alerts, while milder cases receive educational guidance. Data collected is shared with healthcare providers. Educational health content has been created by professionals, encompassing cancer-specific topics, healthcare processes, administration, health coverage, self-awareness, and self-care practices. The content is based on scientific evidence, official reports, and group sessions involving healthcare professionals and cancer patients.
Study: NCT06173973

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kenetik; Ketone Concentrate
Description: Ketone Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric dextrose placebo
Description: Drink that is taste and visually matched to Ketone supplement
Study: NCT03280186

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
Study: NCT05956080

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Allergy testing
Description: University Medicine Greifswald
Study: NCT05237609

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rehabilitation with muscle strengthening + Oral Nutritional Supplements
Description: Combination of protein intake and muscle strengthening exercises for the improvement of walking capacities, patients in the experimental group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation with muscle strengthening
Description: Physical activity with only muscle strengthening
Study: NCT05230693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sarcoidosis Patient Assessment and Resource Companion App
Description: The first group, called the SPARC group will be asked to download the SPARC app onto the participant's smartphone, will be shown how to use the app, and then will be asked to use the app to do guided meditations for ten minutes twice a day
Study: NCT04483206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05545865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 1 serving
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate - 1 serving
Description: Measure the response 2 and 6 hours post chocolate intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate covered almonds
Description: Measure the response 2 and 6 hours post chocolate covered almond intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate covered almonds
Description: Measure the response 2 and 6 hours post chocolate covered almond intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vine to Bar Chocolate covered almonds
Description: Measure the response 2 and 6 hours post chocolate covered almond intake
Study: NCT04900519

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6643
Description: Anti-CD47 human monoclonal antibody
Study: NCT06177821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum®
Description: Rezum® Water vaporization device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum®
Description: Rezum® Water vaporization device
Study: NCT00105846

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Home care telemedicine
Study: NCT05652907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSD201
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to FSD201 for oral administration.
Study: NCT05230693

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care
Description: Participants will receive education about reducing fatigue associated with sarcoidosis during a normal clinic visit.
Study: NCT04020224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amustaline/GSH pathogen reduction technology
Description: Whole blood treated with pathogen reduction technology
Study: NCT05259644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy
Description: Surgical procedure - laparoscopic sleeve gastrectomy.
Study: NCT04020224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Red Blood Cell Component or whole blood
Study: NCT05779501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered strengths use intervention
Description: The online strengths use intervention program follows the theorized five stages of strengths use interventions: (1) preparation and commitment, (2) identification, (3) integration, (4) action, and (5) evaluation. To increase participant engagement and motivation, gamification components are embedded in several stages.~The intervention was previously tested through a feasibility and acceptability trial (NCT05474807).~The entire intervention will be delivered online via an LMS software solution.
Study: NCT05259644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment of obesity
Description: Diet and exercise
Study: NCT05779501

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waiting-list
Description: The waiting-list arm will serve as the control group, filling in only the outcome measure at the same time as the intervention group participants.~After the intervention group finishes participating in the intervention, the waiting-list participants will benefit from the same internet-delivered strengths use program.
Study: NCT06185881

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of cervical carious teeth
Description: restoration of carious cervical lesions by glass ionomer
Study: NCT05259644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic gastric plication
Description: Endoscopic procedure - endoscopic gastric plication
Study: NCT06185881

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restoration of cervical carious teeth
Description: restoration of carious cervical lesions by glass ionomer
Study: NCT05149131

Intervention type: DRUG
Intervention: ADT (Eligard®*) with or without treatment intensification
Description: Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix
Study: NCT04537364

Intervention type: DIAGNOSTIC_TEST
Intervention: combined diagnosis of renal parenchymal damage
Description: This study is an observational study to evaluate the accuracy of renal parenchymal damage combined diagnosis with no intervention. All patients from the cohort accept MRI-DWI scan，the urinary biomarkers detection, disease gene detection and DMSA scan.~1. This combined diagnosis includes MRI-DWI scan and the urinary biomarkers detection.~   MRI-DWI： All the scans are performed using the MagnetomVerio 3.0T magnetic resonance imaging system from Siemens.~   Urinary polypeptide collection: Urine samples requirements: volume between 50-100ml, specific gravity \>1.010. Immunomagnetic beads isolation technique is used to collect polypeptide.~2. The reference standard is DMSA scan: Intravenous injection of 99mTC-DMSA5mCi is followed by anterior and posterior planar imaging of the renal area 1 hour later. The DMSA scan images are read by 2 trained radiologists and confirmed by the special doctor of the center for diagnosis and treatment of renal and urinary diseases at the same time.
Study: NCT05675202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3525
Description: TQ-B3525 is a new PI3K α/δ Kinase inhibitor
Study: NCT04810676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-383
Description: QD, PO
Study: NCT05483855

Intervention type: OTHER
Intervention: Objective 1 Only: Telehealth Satisfaction Survey
Description: Participants must complete a telehealth satisfaction survey rating their standard of care telehealth visit on a scale of 1 to 10, with 1 denoting low satisfaction and 10 denoting high satisfaction.
Study: NCT06172634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dentritic cell infusion and immunecheckpoint inhibitor
Description: dentritic cell infusion and immunecheckpoint inhibitor
Study: NCT05352412

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making Aid
Description: Patients will be randomized to the shared decision making aid intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Counseling As usual
Description: Patients will be randomized to the baseline counseling as usual.
Study: NCT04467476

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
Study: NCT06342115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane-Tazobactam
Description: In the intervention arm 3g of ceftolozane-tazobactam are given intravenously every 8 hours. Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: The comparator arm consists of 2g of meropenem given intravenously every 8 hours.Duration of therapy should follow local guidelines and de-escalation is allowed after identification of causative pathogens.